Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 4/20 | 0.57 |
| ▸ | HCN4 | Q9Y3Q4 | 6/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CCL2 | P13500 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | DRD3 | P35462 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | KCNN2 | Q9H2S1 | 3/20 | 0.31 |
| ▸ | KCNN3 | Q9UGI6 | 3/20 | 0.31 |
| ▸ | KCNN1 | Q92952 | 1/20 | 0.31 |
| ▸ | PDE4A | P27815 | 1/20 | 0.31 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15047162 | 0.93 | BRD4 (0.55) | BRD4HCN4GAASMN1; SMN2CCL2 | |
| SCHEMBL20254176 | 0.81 | BRD4 (0.68) | BRD4HCN4GAASMN1; SMN2CCL2 | |
| SCHEMBL15043263 | 0.81 | BRD4 (0.33) | BRD4 | |
| SCHEMBL15858417 | 0.81 | BRD4 (0.63) | BRD4HCN4GAASMN1; SMN2CCL2 | |
| SCHEMBL10978343 | 0.80 | BRD4 (0.66) | BRD4HCN4GAASMN1; SMN2CCL2 | |
| SCHEMBL22738847 | 0.80 | BRD4 (0.66) | BRD4HCN4GAASMN1; SMN2CCL2 | |
| SCHEMBL10986173 | 0.80 | BRD4 (0.58) | BRD4HCN4GAASMN1; SMN2CCL2 | |
| SCHEMBL18870119 | 0.79 | BRD4 (0.64) | BRD4HCN4GAASMN1; SMN2CCL2 | |
| SCHEMBL15858418 | 0.79 | BRD4 (0.64) | BRD4HCN4GAASMN1; SMN2CCL2 | |
| SCHEMBL10664582 | 0.78 | BRD4 (0.63) | BRD4HCN4GAASMN1; SMN2CCL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2566850-B1 | INDUSTRIAL PROCESS FOR THE SYNTHESIS OF IVABRADINE HYDROBROMIDE SALT | RICHTER GEDEON NYRT (HU) | 2018-04-11 | — | — | EP | disclosed |
| US-9506095-B2 | Process for the enzymatic synthesis of (7S)-3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-triene-7-carboxylic acid or esters thereof, and application in the synthesis of ivabradine and salts thereof | LES LABORATORIES SERVIER (FR) | 2016-11-29 | — | — | US | disclosed |
| US-9476071-B2 | Process for the enzymatic synthesis of (7S)-3,4-dimethoxybicyclo[4.2.0]OCTA-1,3,5-triene-7-carboxylic acid and application in the synthesis of ivabradine and salts thereof | LES LABORATOIRES SERVIER (FR) | 2016-10-25 | — | — | US | disclosed |
| EP-2772547-B1 | Method for enzymatic synthesis of (7S)-3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-triene-7-carboxylic acid, and use for the synthesis of ivabradine and the salts thereof | SERVIER LAB (FR) | 2015-07-08 | — | — | EP | disclosed |
| EP-2687506-B1 | Method for enzymatic synthesis of (7S)-1-(3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-triene-7-yl) N-methyl methanamine, and use for the synthesis of Ivabradine and the salts thereof | SERVIER LAB (FR) | 2015-06-24 | — | — | EP | disclosed |
| US-9045788-B2 | Process for the enzymatic synthesis of (7S)-1-(3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl) N-methyl methanamine, and application in the synthesis of ivabradine and salts thereof | LES LABORATOIRES SERVIER (FR) | 2015-06-02 | — | — | US | disclosed |
| EP-2626428-B1 | Method for enzymatic synthesis of (7S)-3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-triene-7-carboxylic acid or the esters thereof, and use for the synthesis of ivabradine and the salts thereof | SERVIER LAB (FR) | 2015-05-27 | — | — | EP | disclosed |
| WO-2014131996-A1 | METHOD FOR THE ENZYMATIC SYNTHESIS OF (7S) 3,4-DIMETHOXYBICYCLO[4.2.0]OCTA-1,3,5-TRIENE 7-CARBOXYLIC ACID AND USE THEREOF IN THE SYNTHESIS OF IVABRADINE AND SALTS THEREOF | LES LABORATOIRES SERVIER (FR) | 2014-09-04 | — | — | WO | disclosed |
| EP-2772547-A1 | Method for enzymatic synthesis of (7S)-3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-triene-7-carboxylic acid, and use for the synthesis of ivabradine and the salts thereof | Les Laboratoires Servier (FR) | 2014-09-03 | — | — | EP | disclosed |
| US-20140242644-A1 | PROCESS FOR THE ENZYMATIC SYNTHESIS OF (7S)-3,4-DIMETHOXYBICYCLO[4.2.0]OCTA-1,3,5-TRIENE-7-CARBOXYLIC ACID AND APPLICATION IN THE SYNTHESIS OF IVABRADINE AND SALTS THEREOF | LES LABORATOIRES SERVIER (FR) | 2014-08-28 | — | — | US | disclosed |
| US-20070135411-A1 | Process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid | LES LABORATOIRES SERVIER (FR) | 2007-06-14 | — | — | US | disclosed |
| EP-1589005-B1 | Process for the synthesis of Ivabradine and its pharmaceutically acceptable acid addition salts | SERVIER LAB (FR) | 2007-03-28 | — | — | EP | disclosed |
| US-7176197-B2 | Process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid | LES LABORATOIRES SERVIER (FR) | 2007-02-13 | — | — | US | disclosed |
| US-7064200-B2 | Process for the synthesis of 1,3,4,5-tetrahydro-2H-3-benzazepin-2-one compounds, and application in the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid | LES LABORATOIRES SERVIER (FR) | 2006-06-20 | — | — | US | disclosed |
| EP-1614687-A1 | Process for the preparation of 1,3,4,5-tetrahydro-2H-3-benzazepin-2-one derivatives and their application in the synthesis of ivabradine and its pharmaceutically acceptable salts | LES LABORATOIRES SERVIER (FR) | 2006-01-11 | — | — | EP | disclosed |
| WO-2005111027-A1 | NOVEL METHOD OF SYNTHESISING 1,3,4,5-TETRAHYDRO-2H-3-BENZAZEPIN-2-ONE DERIVATIVES AND USE THEREOF IN THE SYNTHESIS OF IVABRADINE AND THE SALTS THEREOF FOR ADDITION TO A PHARMACEUTICALLY ACCEPTABLE ACID | LES LABORATOIRES SERVIER (FR) | 2005-11-24 | — | — | WO | disclosed |
| WO-2005110993-A1 | NOVEL METHOD OF SYNTHESISING IVABRADINE AND THE SALTS THEREOF FOR ADDITION TO A PHARMACEUTICALLY ACCEPTABLE ACID | LES LABORATOIRES SERVIER (FR) | 2005-11-24 | — | — | WO | disclosed |
| EP-1589005-A1 | Process for the synthesis of Ivabradine and its pharmaceutically acceptable acid addition salts | LES LABORATOIRES SERVIER (FR) | 2005-10-26 | — | — | EP | disclosed |
| US-20050228177-A1 | Process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid | LES LABORATOIRES SERVIER (FR) | 2005-10-13 | — | — | US | disclosed |
| US-20050228178-A1 | Process for the synthesis of 1,3,4,5-tetrahydro-2H-3-benzazepin-2-one compounds. and application in the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid | LES LABORATOIRES SERVIER (FR) | 2005-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135411-A1 | Process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid | SCN5A, NISCH, CYP4F2 | BRD4 4110/4885HCN4 9/4885GAA 642/4885 |
| US-20050228177-A1 | Process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid | SCN5A, NISCH, CYP4F2 | BRD4 4013/4885HCN4 10/4885GAA 709/4885 |
| US-20050228178-A1 | Process for the synthesis of 1,3,4,5-tetrahydro-2H-3-benzazepin-2-one compounds. and application in the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid | BDKRB2, BDKRB1, HCN1 | BRD4 1156/4885HCN4 22/4885GAA 1931/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.